



Acute renal failure in the cardiac intensive 
care unit – A practical approach to management
INTRODUCTION                                                                 
There is a strong and well-established association between cardiovascular 
disease and chronic kidney disease (CKD); however, the association 
between cardiovascular disease and acute renal failure (ARF) and 
acute-on-chronic renal failure is less well defi ned. What is clear is that, 
in the cardiac intensive care unit (CICU), the presence of ARF imparts 
a signifi cant mortality, where up to 50% may die. Furthermore, the 
common association of diabetes and cardiovascular disease is further 
complicated by the concomitant risk of kidney disease. As the population 
ages, with its increasing comorbidities and acuity of illness, and the 
epidemic of cardiovascular disease continues to rise, we are likely to see 
more patients developing ARF in the CICU setting. Prevention and 
management of this development are of paramount importance to 
improve overall outcome of these patients and to practise cost-effective 
medicine.
Elderly patients are more likely to have comorbidities and more likely 
to develop renal failure, in association with percutaneous and surgical 
coronary interventions.
With judicious preventative strategies and aggressive management, 
survival rates have improved, especially when adjusted for illness 
severity.(1) 
DEFINITION OF ACUTE RENAL FAILURE                    
A widely accepted and systematic defi nition of ARF has been lacking, 
which has led to signifi cant confusion both clinically and in the medical 
literature. In 2004, the Acute Dialysis Quality Initiative (ADQI) group 
published the RIFLE (Risk, Injury, Failure, Loss, End-stage kidney disease) 
classifi cation of ARF, based on changes from the patient’s baseline either 
in serum creatinine level or glomerular fi ltration rate (GFR), urine 
output (UO), or both.(2) Although not universally accepted, we feel this 
provides an appropriate defi nition.  
The RIFLE classifi cation of ARF is as follows: 
■  Risk (R) - Increase in serum creatinine level X 1.5 or decrease in 
GFR by 25%, or UO <0.5 mL/kg/h for 6 hours 
■  Injury (I) - Increase in serum creatinine level X 2.0 or decrease in 
GFR by 50%, or UO <0.5 mL/kg/h for 12 hours 
■  Failure (F) - Increase in serum creatinine level X 3.0, decrease 
in GFR by 75%, or serum creatinine level > 350 umol/l; UO 
<0.3 mL/kg/h for 24 hours, or anuria for 12 hours 
■ Loss (L) - Persistent ARF, complete loss of kidney function >4 wk 
■ End-stage kidney disease (E) - Loss of kidney function >3 months
Since baseline GFRs are not readily available, the consensus committee 
recommended the use of the Modifi cation of Diet in Renal Disease 
(MDRD) equation to calculate the GFR. Most pathology laboratories in 
South Africa supply this calculation with the urea and electrolyte 
results.
AETIOLOGIES OF ARF IN THE CICU                             
Considering the common association between acute cardiac disease, 
hypotension and renal failure, it is not suprising that the prevailing 
aetiology of ARF in the CICU relates to hypotension. Other pathogenic 
mechanisms are involved, as outlined in (Figure 1).
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 The association between cardiovascular disease 
and acute renal failure (ARF) and acute-on-chronic renal failure is 
less well defi ned. In the cardiac intensive care unit (CICU), the 
presence of ARF imparts a signifi cant mortality. The predominant 
aetiology of ARF in the CICU relates to hypotension, although other 
causes are certainly involved too, and both contrast nephropathy 
and cholesterol embolisation may be associated with percutaneous 
coronary intervention. Despite the availability of renal replacement 
therapies, preventative measures remain the most important 
element of management. Specifi c therapy includes management of 
the patient’s volume status, vasoactive medication and renal 
replacement therapy in the way of dialysis. In the setting of acute 
renal failure, both patient and renal outcome is improved with the 
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Volume depletion, hypotension and cardiogenic shock
Reduced cardiac output (CO) due to hypovolemia or cardiac 
dysfunction (acute MI, CHF, and arrhythmia) diminishes renal perfusion 
both directly and indirectly. Cardiogenic shock is a progressive state of 
hypotension (systolic blood pressure < 90 mm Hg) lasting at least 30 
minutes, which leads to systemic hypoperfusion and is generally more 
common in patients with ST-segment elevation myocardial infarction 
than in patients with other acute coronary syndromes.(3) 
Decreased CO lowers renal blood fl ow and activates a number of 
renal vasoconstrictor systems, which increase reno-vascular resistance 
(RVR). Neurohumoral responses (sympathetic nervous system, renin 
angiotensin aldosterone system (RAAS), vasopressin secretion) have 
opposing effects on renal perfusion, tending to augment renal perfusion 
pressure, but also resulting in renal vasoconstriction. Any intervention 
restoring CO and systemic perfusion therefore augments renal 
perfusion by reversing the aforementioned infl uences.(4) 
The history in some patients often includes a decrease in fl uid intake, 
vomiting and diarrhoea, haemorrhage, sepsis and/or excessive diuresis, 
all of which may have precipitated the acute cardiac event resulting in 
admission to the CICU.(5) Such patients may demonstrate a low jugular 
venous pressure, tachycardia, and postural hypotension. Kidney 
dysfunction associated with hypovolemia and low CO improves 
following volume replacement, inotropic support in those unresponsive 
to fl uids, and improved myocardial function. Monitoring intravascular 
fl uid status requires a combination of clinical parameters, central venous 
pressure, central venous oxygenation (via the CVP line), and lactate 
levels. However, suffi cient improvement may be diffi cult to achieve in 
the setting of intractable myocardial dysfunction and/or cardiogenic 
shock where immediate revascularisation, where applicable, is associated 
with better outcome.(6)  
Congestive heart failure
ARF is a common complication among patients hospitalized for CHF, 
out of the setting of acute coronary ischemia, and is associated with 
increased risk for adverse outcomes. Approximately 50% of patients 
hospitalised for heart failure have preserved systolic function; however, 
if their systolic blood pressure is less than 125 mmHg their risk of acute 
renal failure increases, as does their mortality risk.(7) Risk factors for ARF 
from CHF include diabetes, elevated admission serum creatinine and 
reduced serum sodium and echocardiographic demonstration of 
diastolic dysfunction.(8) 
Percutaneous coronary intervention
The two common causes of renal failure following PCI are contrast 
nephropathy (CN) and cholesterol embolisation (CE). 
Cholesterol embolisation syndrome is a systemic disease caused by distal 
showering of cholesterol crystals after angiography, major vessel surgery, 
or thrombolysis. It is relatively rare following coronary intervention, and 
those patients with an elevated CRP pre-procedure may be at greater 
risk for its development. More than 60% of patients suffering from this 
syndrome develop renal insuffi ciency.(9) 
Part of the diffi culty in making the diagnosis relates to the time interval 
(typically one to four weeks but occasionally several months) between 
intervention and disease onset, which tends to obscure the causative 
link. In the context of renal disease, this delay in onset and subsequent 
progressive deterioration in renal function can help to distinguish 
cholesterol embolism from contrast nephropathy (see below). Given 
our inability to reverse the condition, early diagnosis is crucial if further 
episodes of cholesterol emboli are to be prevented. Statin therapy 
may stabilise plaques and a highly conservative approach, avoiding 
anticoagulation, angiography and vascular surgery, may produce the 
best outcome. Renal failure often progresses to dependence on 
dialysis.(10) 
Importantly, acute renal failure that requires dialysis after percutaneous 
coronary interventions is associated with very high in-hospital and 
1-year mortality rates and a dramatic increase in hospital resource 
utilization.(11) 
PCI and contrast nephropathy
Although defi nitions may vary, a commonly accepted and applied 
defi nition of contrast nephropathy is a > 25% increase in serum 
creatinine level that occurs within 48 hours of contrast exposure.(12) 
Once CN occurs, kidney function may remain depressed for 1-3 weeks 
depending on the severity of the insult, but returns to normal or near 
normal in most cases.(13)  The presence of predisposing risk factors 
(Table 1) increases the risk of CN and, in the elderly patient undergoing 






 FIGURE 1: Pathophysiological mechanisms of ARF(35) 
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Vasodilators (PGI (2), NO)
The most important risk factors seem to be the presence of pre-
existing kidney insuffi ciency, diabetes mellitus, fl uid depletion, the elderly 
and the volume of contrast used.(14) The use of nonionic agents(15) 
appears to lower the incidence of CN and this has been confi rmed in 
animal models.(16) 
Recommendations for management of contrast nephropathy depend 
on the underlying kidney function.(17) In those patients with normal 
serum creatinine, adequate hydration is all that is necessary. Although 
serum creatinine levels may be normal, diabetics, elderly patients and 
those with reduced muscle mass may have a normal U&E although 
their creatinine clearance may be reduced, thereby imparting a risk for 
CN. In this setting, a calculated creatinine clearance would be more 
appropriate. In those with moderate kidney insuffi ciency (creatinine 
150mmol/l-250mmol/l, creatinine clearance <50ml/min) intravenous 
volume administration with saline 0.45% or 0.9% for 12 hours before 
and 6 hours after the procedure. Recent data suggests that isotonic 
sodium bicarbonate may be more protective, although this has not 
been substantiated.(18) Iso-osmolar contrast agents with judicious dose 
limitation may also reduce the risk of CN and repeat procedures should 
be delayed as long as possible. Acetylcysteine 600mg bid on the day 
before and on the day of the procedure is advocated, though the 
benefi t of this agent is controversial. Severe kidney insuffi ciency 
(creatinine >250mmol/l, creatinine <30ml/min) imparts a risk of 
irreversible kidney failure despite the abovementioned preventative 
measures. Such a risk should be discussed with the patient prior to the 
intervention and the need for the intervention should be debated.
Although the overall incidence of ARF after PCI is low, acute renal 
insuffi ciency after PCI is a strong and independent predictor of long-
term mortality in patients who survive for 30 days after the procedure.(19) 
Diabetic patients with baseline serum creatinine values <170 umol/l 
are at higher risk than nondiabetic patients, whereas all patients with a 
serum creatinine >170 umol/l are at high risk for ARF.(20) 
Sepsis
Although sepsis is a common cause of acute renal failure in the general 
intensive care unit, it is an unusual occurrence in the coronary care unit. 
Its presence as a primary disease, however, may precipitate an acute 
cardiac event.(21) The classical pathogenic mechanism of septic acute 
renal failure revolves around haemodynamic disease where fl uid 
resuscitation aims to prevent and restore renal function. Recently, 
however, Wan et al. reviewed the subject and suggested that, indeed, 
acute tubular apoptosis may underlie the renal effects of sepsis, and 
management of precipitants may improve renal outcome.(22) Animal 
studies suggest that protein C has anti-infl ammatory and anti-apoptotic 
functions, which are reduced in acute sepsis especially when acute renal 
failure is induced. In these studies treatment of septic animals with 
activated protein C improved renal function, suggesting anti-apoptosis.(23) 
Mechanical ventilation causes pulmonary biotrauma, with a resultant 
pulmonary infl ammatory reaction that may generate systemic release 
of infl ammatory mediators, which have apoptotic effects, especially in 
the kidney. In theory, low volume mechanical ventilation may reduce 
such mediators and their renal side-effects.(24) Intensive insulin therapy 
improves outcome in the ICU patient where strict glucose control 
seems to improve dysregulated apoptosis, which may aid in recovery 
from renal failure.(25,26) 
Appropriate antibiotic usage adjusted for renal function and/or dialysis 
is equally important in controlling sepsis and its consequences.
Medication
Both cardiovascular disease and chronic kidney disease are frequently 
managed with ACE inhibitors, and there is strong evidence of better 
outcomes in both. However, ACE inhibitors can exacerbate or cause 
ARF in some settings. ACE inhibitor induced ARF occurs in settings 
where glomerular afferent arteriolar blood fl ow is reduced, in 
which case GFR is dependent on aII mediated efferent arteriolar 
vasoconstriction. It should be stressed that ACE inhibitor induced ARF 
is not dependent on a drop in blood pressure or renal blood fl ow by 
the use of an ACE inhibitor. Indeed, in the presence of a signifi cant renal 
artery stenosis, renal blood fl ow and GFR are blood pressure dependent 
and any intensifi cation of antihypertensive treatment can cause reduced 
GFR. Having said that, subgroup analyses of the HOPE study indicate 
that ACE inhibition with ramipril is benefi cial without an increased risk 
of adverse effects like acute renal failure or hyperkalemia.(27) Thus the 
frequent practice of withholding ACE inhibitors from patients with mild 
renal insuffi ciency is unwarranted, especially as this might identify a 
group at high risk who appear to benefi t most from treatment. There 
may be a place for acute withdrawal of the ACE inhibitor in the CCU 
setting when the patient is haemodynamically unstable or where the 
creatinine is rising acutely. However, the use of ACE inhibition 20 or 
more days post myocardial infarction has proven morbidity and 
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TABLE 1: Strategies to reduce ARF
Avoid nephrotoxins: Optimise renal perfusion: Low-dose dopamine
NSAIDS, Aminoglycosides Fluids and /or inotropic  Mannitol
 support Diuretics
 N-acetylcysteine Aminophylline
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mortality benefi t and, although this may reduce glomerular pressure 
acutely with mild increase in serum creatinine, the serum creatinine 
then stabilises and in most cases returns to baseline. 
Statins are used by millions of people worldwide and only rarely cause 
severe side effects, the most sinister of which is rhabdomyolysis induced 
ARF. To this end, the American Heart Association lists a group of 
patients most at risk of severe myopathy and these include: advanced 
age, multisystem disease (e.g. chronic renal failure, especially if caused by 
diabetes), perioperative periods, multiple medications (especially 
gemfi brozil, and cytochrome P3A4 interactors cyclosporine, itraconazole 
and ketoconazole, macrolide antibiotics, erythromycin and clarithromycin, 
HIV protease inhibitors in those on statins using this metabolic pathway) 
and alcohol abuse.(28) 
Since the timing of this toxicity is unpredictable, routine screening is not 
recommended. Therefore, patients should be made aware of muscle 
symptoms and promptly discontinue the statin when these occur while 
awaiting laboratory (creatine kinase) assessment.
MANAGEMENT STRATEGIES                                           
Despite the availability of renal replacement therapies, preventative 
measures remain the most important element of management. Table 1 
outlines such therapies, although predicting who may be at risk for ARF, 
especially from contrast (Table 2), could circumvent its development. 
Patients with acute cardiac events often have a preceding history of 
hypertension. This results in the autoregulatory level of renal blood 
fl ow being set at a higher level and renal blood fl ow decreases 
signifi cantly when the mean arterial blood pressure falls below 80mmHg, 
severely compromising renal perfusion and function.(29) These patients 
are at particular risk of hypoperfusion. 
Reversal of a compromised haemodynamic state with inotropic 
support, appropriate fl uid resuscitation and primary coronary 
intervention seems prudent in acutely compromised cardiac patients. 
Furthermore, removal of any nephrotoxic agents and precipitating 
factors are critical. Volume therapy is the cornerstone of initial 
management of the hypotensive patient and strict CVP monitoring is 
recommended. The rate and composition of the volume expanders is 
determined by the working diagnosis. Cardiogenic causes without 
evidence of fl uid overload require small volume challenges (250 ml) of 
crystalloid or perhaps hydroxyethyl starch titrated to clinical response 
(increased BP, decreased heart rate, increased urine output). 
Hypovolemic states require larger volumes of crystalloid, again titrated 
to response and underlying cardiac function. In this setting non-oliguric 
patients presenting with ARF have fewer complications, including a 
decreased dialysis requirement and improved survival.(30) Although 
conversion of an oliguric patient to non-oliguria has less certain benefi t, 
it can often be accomplished by repleting volume as above, and adding 
a loop diuretic titrated to urine output and blood pressure. An infusion 
of furosemide 250 mg in 200 ml normal saline can easily be adjusted to 
clinical response, but only once both blood pressure and central venous 
pressure are adequate. 
Vasoactive therapy and monitoring should be simplifi ed and goal-
directed and reduced and discontinued when stability is achieved.(4) The 
clinician must determine whether there is evidence of low cardiac output 
with high cardiac fi lling pressures that requires inotropic support or 
hypotension is accompanied by a high cardiac output state that requires 
pressor support. Generally speaking, beta agonists are chosen for support 
of cardiac output and alpha agonists are chosen when maintenance of 
perfusion pressure is needed to maintain blood fl ow to the tissues, 
including the kidneys. Common alpha agonists are phenylephrine and 
noradrenalin. Noradrenalin will raise mean arterial pressure at the 
expense of cardiac output and thus cardiac output should be adequate 
before its initiation. Dobutamine (beta-agonist) will increase cardiac 
output but will also vasodilate and thus venous return may need 
augmentation with a fl uid bolus. Adrenaline has both alpha and beta 
effects and is used in resuscitation and severe hypotension. One must 
remember that long-term usage leads to tissue ischemia, the resultant 
acidosis of which may reduce effectiveness of other inotropic agents.  
Importantly, whilst a renal vasodilator dose of dopamine (1.5 to 
2.5 ug/kg/min) may stimulate urine volume, it does not improve GFR, 
shorten the duration of ARF, or decrease dialysis requirements.(31) In 
addition, dopamine may induce signifi cant arrhythmia and possibly 
intestinal ischemia.
Many patients with ARF will recover renal function within days and not 
require renal replacement therapy (RRT). However, if the duration of 
ARF is prolonged, or if hyperkalemia, extracellular volume overload, 
refractory acidosis or uremic symptoms (serositis, encephalopathy, 
TABLE 2: Risk factors for contrast nephropathy
1. Serum creatinine > 150 mol/l
2.  Diabetic nephropathy
3.  Older age
4.  Class III/IV congestive heart failure
5.  Volume and osmolality of contrast media used
8bleeding) occur, some form of renal replacement therapy may be 
necessary. The major goal of RRT in ARF is to maintain the patient’s 
survival while awaiting recovery of renal function. Its two main objectives 
are 1) to control ECV by removal of excess fl uid (ultrafi ltration) and 2) 
to control uremia by removal of excess solute (dialysis). Depending on 
a patient’s needs, these two objectives can be accomplished separately 
or simultaneously, intermittently or continuously, by peritoneal or 
hematogenous access.
With no clear survival advantage established, the clinician is free to 
target a particular RRT modality to any given patient and, in fact, dialysis 
therapy should be individualised.(32) When rapid solute control is 
necessary, e.g. severe hyperkalemia or volume overload, intermittent 
haemodialysis is most suitable. For hypotensive patients requiring 
inotropic support, continuous forms of dialysis such as continuous 
veno-veno haemodialysis may be more appropriate. They allow for 
more gentle fl uid removal without further compromising the patient’s 
haemodynamic status. 
Regardless of the particular RRT selected, the clinician must ensure an 
adequate dose of dialysis. Currently, no measure of dialysis adequacy 
allows comparison of different RRTs applied to patients with ARF.(33) 
Peritoneal dialysis (PD) plays a relatively minor role as an RRT in the 
CICU. Nevertheless, it offers several advantages including simplicity, 
hemodynamic stability and freedom from anticoagulation. Automated 
cyclers easily accomplish the exchange of dialysate; however, even with 
frequent dialysate exchanges and very hypertonic dialysate, PD 
clearance of solute and UF rates are limited. In addition, the 
intraperitoneal volume of dialysate can compromise respiration, and 
glucose loads and protein losses can be excessive. Therefore, PD 
appears better suited for the less catabolic, less uremic, and relatively 
normovolemic patient.
CONCLUSION                                                                      
The development of ARF in the cardiac ICU patient portends an 
ominous outcome. Assessment and reduction of risk factors for ARF, 
thereby preventing its occurrence, is appropriate in all patients admitted 
and treated. When ARF does occur, early involvement of the kidney 
team (consultation and renal replacement) is likely to improve outcome 
in such patients.(34)
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